Clear Street lowered the firm’s price target on Wave Life Sciences (WVE) to $36 from $39 and keeps a Buy rating on the shares following the Q1 report. The firm continues to believe Wave Life is “significantly undervalued” for WVE-007’s potential in obesity.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WVE: